Revenio Group Corporation, Stock Exchange Release, December 8, 2017 at 9:00
REVENIO GROUP'S FINANCIAL REPORTING AND ANNUAL GENERAL MEETING IN 2018
During 2018, Revenio Group Corporation will publish the following financial reports:
- Financial Statements bulletin in regard to 2017 on Thursday, February 15, 2018
- Interim Report 1-3/2018 on Friday, April 20, 2018
- Interim Report 1-6/2018 on Monday, August 6, 2018
- Interim Report 1-9/2018 on Thursday, October 25, 2018
Due to an amendment in the Securities Market Act, which came into force on 26 November 2015, Revenio will publish the descriptive sections of its interim reports for 1-3/2018 and 1-9/2018 in a concise form. The table sections will be reported in accordance with previous practices.
The Annual General Meeting is planned to be held on Tuesday, March 20, 2018. The Board of Directors will give a separate notice of the Annual General Meeting later.
A shareholder, who wishes to place an item on the agenda of the Annual General Meeting, shall submit the request in writing to the company's Board of Directors by February 3, 2018. Such requests including the reasoning or a resolution proposal can be submitted to the address: Revenio Group Corporation / Board of Directors, Äyritie 22, FI-01510 Vantaa, Finland.
The Annual Report for 2017 will be published on the Group's website www.revenio.fi during week 9 in 2018.
Revenio Group Corporation
For further information, please contact:
Timo Hildén, CEO, tel. +358 40 580 4774
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating margin for continuing operations standing at 30.1%. Revenio Group Corporation is listed on Nasdaq Helsinki.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Revenio Group Corporation via Globenewswire